Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy - an analysis of the DiaRegis registry

Jürgen Wasem,Peter Bramlage,Anselm K. Gitt,Christiane Binz,Michael Krekler,Evelin Deeg,Diethelm Tschöpe

Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy - an analysis of the DiaRegis registry

2013

Jürgen Wasem
Peter Bramlage
Anselm K. Gitt
Christiane Binz
Michael Krekler
Evelin Deeg
Diethelm Tschöpe

Background Type-2 diabetes mellitus has a major impact on health related quality of life (HRQoL). We aimed to identify patient and treatment related variables having a major impact.

Keywords:

Prospective cohort study
Comorbidity
Metformin
Glipizide
Type 2 diabetes
Diabetes mellitus
Combination therapy
Angiology
Medicine
Physical therapy
Endocrinology
Quality of life
in patient
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations